Investors worry about lack of nanoscience regulation

Nanotechnology risks a public backlash similar to that against GM technology because it is being "developed in a regulatory vacuum", according to fund managers Jupiter Asset Management.1 Meanwhile, an influential EU scientific committee says that current approaches to risk assessment are inadequate to deal with nanotechnology, and that each nanoproduct must be assessed on a case-by-case basis.2

Sign in to continue

Sign in

Trouble signing in?

Reset password: Click here


Call: 020 8267 8120

Register for
Free Trial

  • 14 day access to subscriber-only content



Prices on request

  • Full access to for 12 months
  • Monthly print issues
  • Clear and accessible guidance on relevant legislation
  • Integration with ENDS Compliance Manager helping you plan ahead and ensure compliance for your organisation
  • Individual or bespoke multi-user packages available

See all benefits